HLB Panagene
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Panagene develops and supplies diagnostic tools and reagents used to detect genetic information, helping medical professionals identify diseases and conditions at the molecular level.
Its products are used in clinical and research settings, placing the company in the life-science diagnostics supply chain. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company currently generates most of its revenue from its molecular diagnostics product lines.
Summary is AI-generated and may contain errors · figures from DART filings
HLB Panagene in five facts
What does HLB Panagene do?
HLB Panagene develops and supplies diagnostic tools and reagents used to detect genetic information, helping medical professionals identify diseases and conditions at the molecular level.
Where is HLB Panagene listed and in which sector?
HLB Panagene (Korean name: HLB파나진) trades under KRX code 046210 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HLB Panagene?
Its market capitalisation was US$50.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Panagene's latest annual revenue and operating profit?
For fiscal year 2025, HLB Panagene reported revenue of US$11.4M, an operating loss of US$2.6M and a net loss of US$2.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 14.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 12
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 5
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 5
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Panagene reported consolidated results for FY2025: revenue of US$10.4M (+14.04% year on year), an operating loss of US$2.36M and a net loss of US$2.15M.
Earnings · Feb 12 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 19
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 19